Progyny, Inc. (NASDAQ:PGNY – Get Free Report) Chairman David J. Schlanger sold 5,826 shares of the firm’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $37.74, for a total value of $219,873.24. Following the completion of the sale, the chairman now directly owns 86,312 shares of […]
Progyny (NASDAQ:PGNY – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.540-1.590 for the period, compared to the consensus EPS estimate of 0.700. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Progyny […]
Progyny (NASDAQ:PGNY – Get Free Report)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued on Wednesday, Benzinga reports. They currently have a $48.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 44.53% from the stock’s current price. A number of […]
Progyny (NASDAQ:PGNY – Get Free Report) updated its first quarter 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.330-0.350 for the period, compared to the consensus earnings per share estimate of 0.180. The company issued revenue guidance of $285.0 million-$292.0 million, compared to the consensus revenue estimate of $314.0 million. […]
Progyny (NASDAQ:PGNY – Get Free Report) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.12-0.13 for the period, compared to the consensus earnings per share estimate of $0.18. The company issued revenue guidance of $285-292 million, compared to the consensus revenue estimate of […]